5α-Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.

Niamh Doherty Christopher R Cardwell Peter Murchie Christopher Hill Laurent Azoulay Blánaid M Hicks

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2023)

The findings of this study indicate that 5ARi's are unlikely to reduce kidney or bladder cancer risk.

Keyphrases

benign prostatic hyperplasia
lower urinary tract symptoms
spinal cord injury
urinary tract
middle aged